Entity

Time filter

Source Type


Den Hoedt C.H.,University Utrecht | Mazairac A.H.A.,University Utrecht | Van Den Dorpel M.A.,Maasstad Hospital | Grooteman M.P.C.,Medical Center | And 2 more authors.
Contributions to Nephrology | Year: 2011

Online hemodiafiltration may improve clinical outcome in end-stage kidney disease. The supposed mechanism is the improved clearance of uremic toxins by the convective transport which is added to the standard diffusive transport. This review summarizes the effects of hemodiafiltration on mortality, inflammation and health-related quality of life. Copyright © 2011 S. Karger AG, Basel. Source


Chapdelaine I.,Medical Center | Mostovaya I.M.,University Utrecht | Blankestijn P.J.,University Utrecht | Bots M.L.,University Utrecht | And 8 more authors.
Blood Purification | Year: 2014

Background/Aims: Sub-analyses of three large trials showed that hemodiafiltration (HDF) patients who achieved the highest convection volumes had the lowest mortality risk. The aims of this study were (1) to identify determinants of convection volume and (2) to assess whether differences exist between patients achieving high and low volumes. Methods: HDF patients from the CONvective TRAnsport STudy (CONTRAST) with a complete dataset at 6 months (314 out of a total of 358) were included in this post hoc analysis. Determinants of convection volume were identified by regression analysis. Results: Treatment time, blood flow rate, dialysis vintage, serum albumin and hematocrit were independently related. Neither vascular access nor dialyzer characteristics showed any relation with convection volume. Except for some variation in body size, patient characteristics did not differ across tertiles of convection volume. Conclusion: Treatment time and blood flow rate are major determinants of convection volume. Hence, its magnitude depends on center policy rather than individualized patient prescription. © 2014 S. Karger AG, Basel. Source


Mazairac A.H.A.,University Utrecht | Grooteman M.P.C.,Medical Center | Grooteman M.P.C.,Institute for Cardiovascular Research Medical Center aR | Blankestijn P.J.,University Utrecht | And 14 more authors.
Quality of Life Research | Year: 2012

Purpose: Hemodialysis patients undergo frequent and long visits to the clinic to receive adequate dialysis treatment, medical guidance, and support. This may affect health-related quality of life (HRQOL). Although HRQOL is a very important management aspect in hemodialysis patients, there is a paucity of information on the differences in HRQOL between centers. We set out to assess the differences in HRQOL of hemodialysis patients between dialysis centers and explore which modifiable center characteristics could explain possible differences. Methods: This cross-sectional study evaluated 570 hemodialysis patients from 24 Dutch dialysis centers. HRQOL was measured with the Kidney Disease Quality Of Life-Short Form (KDQOL-SF). Results: After adjustment for differences in case-mix, three HRQOL domains differed between dialysis centers: the physical composite score (PCS, P = 0.01), quality of social interaction (P = 0.04), and dialysis staff encouragement (P = 0.001). These center differences had a range of 11-21 points on a scale of 0-100, depending on the domain. Two center characteristics showed a clinical relevant relation with patients' HRQOL: dieticians' fulltimeequivalent and the type of dialysis center. Conclusion This study showed that clinical relevant differences exist between dialysis centers in multiple HRQOL domains. This is especially remarkable as hemodialysis is a highly standardized therapy. © The Author(s) 2011. Source


Van Der Weerd N.C.,Medical Center | Van Der Weerd N.C.,University Utrecht | Grooteman M.P.C.,Medical Center | Grooteman M.P.C.,Institute for Cardiovascular Research Medical Center aR | And 14 more authors.
Nephrology Dialysis Transplantation | Year: 2013

Background. The development of atherosclerosis may be enhanced by iron accumulation in macrophages. Hepcidin-25 is a key regulator of iron homeostasis, which downregulates the cellular iron exporter ferroportin. In haemodialysis (HD) patients, hepcidin-25 levels are increased. Therefore, it is conceivable that hepcidin-25 is associated with all-cause mortality and/or fatal and non-fatal cardiovascular (CV) events in this patient group. The aim of the current analysis was to study the relationship between hepcidin-25 and all-cause mortality and both fatal and non-fatal CV events in chronic HD patients. Methods. Data from 405 chronic HD patients included in the CONvective TRAnsport STudy (NCT00205556) were studied (62% men, age 63.7 ± 13.9 years [mean ± SD]). The median (range) follow-up was 3.0 (0.8-6.6) years. Hepcidin-25 was measured with mass spectrometry. The relationship between hepcidin-25 and all-cause mortality or fatal and non-fatal CV events was investigated with multivariate Cox proportional hazard models. Results. Median (interquartile range) hepcidin-25 level was 13.8 (6.6-22.5) nmol/L. During follow-up, 158 (39%) patients died from any cause and 131 (32%) had a CV event. Hepcidin-25 was associated with all-cause mortality in an unadjusted model [hazard ratio (HR) 1.14 per 10 nmol/L, 95% CI 1.03-1.26; P = 0.01], but not after adjustment for all confounders including high-sensitive C-reactive protein (HR 1.02 per 10 nmol/L, 95% CI 0.87-1.20; P = 0.80). At the same time, hepcidin-25 was significantly related to fatal and non-fatal CV events in a fully adjusted model (HR 1.24 per 10 nmol/L, 95% CI 1.05-1.46, P = 0.01). Conclusion. Hepcidin-25 was associated with fatal and nonfatal CV events, even after adjustment for inflammation. Furthermore, inflammation appears to be a significant confounder in the relation between hepcidin-25 and all-cause mortality. These findings suggest that hepcidin-25 might be a novel determinant of CV disease in chronic HD patients. © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. Source


Van Der Weerd N.C.,Medical Center | Van Der Weerd N.C.,University Utrecht | Grooteman M.P.C.,Medical Center | Grooteman M.P.C.,Institute for Cardiovascular Research Medical Center aR | And 12 more authors.
Blood Purification | Year: 2012

Background/Aims: Guidelines for the management of anemia and iron deficiency in chronic hemodialysis (HD) patients have been developed to standardize therapy and improve clinical outcome. The present study evaluated compliance with anemia guidelines and investigated whether differences between centers were present. Methods: Data on anemia management from patients in the baseline cohort of the CONTRAST study (NCT00205556) were analyzed. 598 chronic HD patients (62% male, age 63.6 ± 14.0 years) from 26 Dutch dialysis centers were included. Results: Mean hemoglobin (Hb) level was 11.9 ± 1.3 g/dl and Hb was ≥11.0 g/dl in 81% of the patients. Compliance with all anemia targets (Hb 11.0-12.0 g/dl, transferrin saturation ratio ≥20%, ferritin 100-500 ng/ml) was reached in 11.6% (95% CI 7.8-17.0) of the patients, with a wide range among centers (4-26%, adjusted for case mix, treatment-related factors and center-specific characteristics). Conclusion: Compliance with anemia targets in stable HD patients was poor and showed a wide variation between treatment facilities. Copyright © 2012 S. Karger AG, Basel. Source

Discover hidden collaborations